Multi-Scale Modeling of Vascular Signaling Units

血管信号单元的多尺度建模

基本信息

  • 批准号:
    10394236
  • 负责人:
  • 金额:
    $ 54.53万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-04-16 至 2024-03-31
  • 项目状态:
    已结题

项目摘要

Project Summary The function of arteries is to deliver oxygen and nutrients necessary to sustain the function and survival of every cell in the body. Arterial diameter, a key determinant of blood flow, is finely tuned by the contractile state of the smooth muscle cells lining the walls of these vessels. To date, however, models of myogenic control of arterial smooth muscle tone have largely been based on data from male myocytes. Yet, recent data from our team suggest that sex-specific features that determine the operation of arterial myocytes are attributable to differences in the spatial organization of signaling complexes formed by the PKC-anchoring protein AKAP150 and CaV1.2 channels, and the manner in which they regulate smooth muscle contractility. Our findings challenge the general applicability of a model for electrical and pharmacological control of the myogenic response based on data from male myocytes and support the view that myogenic responses are differentially regulated in male and female arteries. In this project, we implement a multi-scale systems approach that includes super-resolution imaging, electrophysiology, and computational approaches to rigorously investigate the mechanisms controlling blood flow through the male and female pial-parenchymal circulatory unit under physiological and pathological conditions. Specific aim 1 is to establish the fundamental sex-specific mechanisms controlling Ca2+ influx via CaV1.2 channels in vascular smooth muscle. Specific aim 2 is to determine the impact of the physical organization of type 1 AngII receptors (AngIIR1), AKAP150, PKCα, and CaV1.2 channels on myogenic tone in male and female arterial smooth muscle. Finally, in specific aim 3 we will investigate whether changes in the number and molecular organization of CaV1.2 and AngIIR1/AKAP150/PKCα signaling units differentially alter Ca2+ influx, arterial wall [Ca2+]i, and myogenic tone in male and female smooth muscle during the development of hypertension. This work will lead to the first model of vascular smooth muscle function that incorporates sex- specific variations in protein organization, electrical activity, and Ca2+ signaling during health and disease, which could inform the development of rational strategies for the treatment of hypertension in male and female.
项目摘要 动脉的功能是输送维持每个人的功能和生存所必需的氧气和营养物质。 细胞在体内。动脉直径是血流的一个关键决定因素,它是通过血管的收缩状态来微调的。 平滑肌细胞排列在血管壁上。然而,到目前为止,肌源性控制动脉的模型 平滑肌张力主要基于来自雄性肌细胞数据。然而,我们团队最近的数据显示, 表明决定动脉肌细胞运作的性别特异性特征可归因于差异 PKC锚定蛋白AKAP 150和CaV 1.2形成的信号复合物的空间组织 通道,以及它们调节平滑肌收缩性的方式。我们的发现挑战了 基于来自以下数据的生肌反应的电和药理学控制模型的适用性: 男性肌细胞并支持男性和女性肌源性反应受到差异调节的观点 动脉在这个项目中,我们实现了一个多尺度系统的方法,包括超分辨率成像, 电生理学和计算方法来严格研究控制血液的机制 在生理和病理条件下,通过男性和女性软脑膜实质循环单元的流量 条件具体目标1是建立基本的性别特异性机制控制钙离子内流,通过 血管平滑肌中的CaV1.2通道。具体目标2是确定物理影响 1型血管紧张素Ⅱ受体(AngIIR 1)、AKAP 150、PKCα和CaV1.2通道在肌源性紧张度中的组织化 男性和女性动脉平滑肌。最后,在具体目标3中,我们将研究 CaV1.2和AngIIR 1/AKAP 150/PKCα信号单位的数量和分子结构差异改变 发育过程中雄性和雌性平滑肌的Ca ~(2+)内流、动脉壁[Ca ~(2+)]i和肌源性张力 高血压这项工作将导致第一个模型的血管平滑肌功能,纳入性别- 在健康和疾病期间蛋白质组织、电活动和Ca 2+信号传导的特定变化, 可为男性和女性高血压的合理治疗策略的制定提供信息。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

COLLEEN E CLANCY其他文献

COLLEEN E CLANCY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('COLLEEN E CLANCY', 18)}}的其他基金

Multi-Scale Modeling of Vascular Signaling Units
血管信号单元的多尺度建模
  • 批准号:
    10406687
  • 财政年份:
    2021
  • 资助金额:
    $ 54.53万
  • 项目类别:
Multi-Scale Modeling of Vascular Signaling Units
血管信号单元的多尺度建模
  • 批准号:
    10614418
  • 财政年份:
    2020
  • 资助金额:
    $ 54.53万
  • 项目类别:
Development of the Predictive NeuroCardiovascular Simulator
预测性神经心血管模拟器的开发
  • 批准号:
    10397892
  • 财政年份:
    2018
  • 资助金额:
    $ 54.53万
  • 项目类别:
Development of the Predictive NeuroCardiovascular Simulator
预测性神经心血管模拟器的开发
  • 批准号:
    10001997
  • 财政年份:
    2018
  • 资助金额:
    $ 54.53万
  • 项目类别:
Development of the Predictive NeuroCardiovascular Simulator
预测性神经心血管模拟器的开发
  • 批准号:
    10092300
  • 财政年份:
    2018
  • 资助金额:
    $ 54.53万
  • 项目类别:
Development of the Predictive NeuroCardiovascular Simulator
预测性神经心血管模拟器的开发
  • 批准号:
    10215080
  • 财政年份:
    2018
  • 资助金额:
    $ 54.53万
  • 项目类别:
In silico safety pharmacology
计算机安全药理学
  • 批准号:
    10480737
  • 财政年份:
    2016
  • 资助金额:
    $ 54.53万
  • 项目类别:
In silico safety pharmacology
计算机安全药理学
  • 批准号:
    10576790
  • 财政年份:
    2016
  • 资助金额:
    $ 54.53万
  • 项目类别:
In silico Safety Pharmacology
计算机安全药理学
  • 批准号:
    9176961
  • 财政年份:
    2016
  • 资助金额:
    $ 54.53万
  • 项目类别:
In silico Safety Pharmacology
计算机安全药理学
  • 批准号:
    9288209
  • 财政年份:
    2016
  • 资助金额:
    $ 54.53万
  • 项目类别:

相似海外基金

Early endothelial function activation by angiotensin II receptor blockers prevents vascular damage in a model of diabetes
血管紧张素 II 受体阻滞剂早期激活内皮功能可预防糖尿病模型中的血管损伤
  • 批准号:
    493141
  • 财政年份:
    2023
  • 资助金额:
    $ 54.53万
  • 项目类别:
Clinical benefits and mechanism of action of angiotensin-II receptor blocker on Cardiovascular remodeling in patients with repaired coarctation of aorta
血管紧张素II受体阻滞剂对主动脉缩窄修复患者心血管重塑的临床疗效及作用机制
  • 批准号:
    10734120
  • 财政年份:
    2023
  • 资助金额:
    $ 54.53万
  • 项目类别:
Targeting cancer-associated fibroblasts and tumour hypoxia with angiotensin II receptor blockers
使用血管紧张素 II 受体阻滞剂靶向癌症相关成纤维细胞和肿瘤缺氧
  • 批准号:
    445961
  • 财政年份:
    2021
  • 资助金额:
    $ 54.53万
  • 项目类别:
    Operating Grants
Antitumor effect of HCC and exosome microRNA by angiotensin II receptor blockers and molecular target drugs
血管紧张素II受体阻滞剂和分子靶向药物对HCC和外泌体microRNA的抗肿瘤作用
  • 批准号:
    19K17401
  • 财政年份:
    2019
  • 资助金额:
    $ 54.53万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Pleiotropic activation of endothelial function by angiotensin II receptor blockers is crucial to their protective anti-vascular remodeling effects
血管紧张素 II 受体阻滞剂对内皮功能的多效性激活对其保护性抗血管重塑作用至关重要
  • 批准号:
    411570
  • 财政年份:
    2019
  • 资助金额:
    $ 54.53万
  • 项目类别:
Heterogeneity of Angiotensin II Receptor Blockers in the inhibition of Marfan-associated Aortic Root Dilation Independent of Blood Pressure Effects
血管紧张素 II 受体阻滞剂抑制马凡相关主动脉根部扩张的异质性,与血压影响无关
  • 批准号:
    391615
  • 财政年份:
    2018
  • 资助金额:
    $ 54.53万
  • 项目类别:
Relationship between serum EETs concentrations and cardiovascular events in patients taking angiotensin II receptor blockers
服用血管紧张素II受体阻滞剂的患者血清EETs浓度与心血管事件的关系
  • 批准号:
    26460229
  • 财政年份:
    2014
  • 资助金额:
    $ 54.53万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The development of new angiotensin II receptor vaccine
新型血管紧张素II受体疫苗的研制
  • 批准号:
    25870715
  • 财政年份:
    2013
  • 资助金额:
    $ 54.53万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Central GRK5 modulation of Angiotensin II receptor expression in heart failure
GRK5 对心力衰竭中血管紧张素 II 受体表达的中枢调节
  • 批准号:
    8531707
  • 财政年份:
    2012
  • 资助金额:
    $ 54.53万
  • 项目类别:
Central GRK5 modulation of Angiotensin II receptor expression in heart failure
GRK5 对心力衰竭中血管紧张素 II 受体表达的中枢调节
  • 批准号:
    8397394
  • 财政年份:
    2012
  • 资助金额:
    $ 54.53万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了